Maps Counseling Services, Inc. | |
23 Central Sq # 300 Keene NH 03431-3707 | |
(603) 355-2244 | |
Not Available |
Full Name | Maps Counseling Services, Inc. |
---|---|
Speciality | Psychologist |
Location | 23 Central Sq # 300, Keene, New Hampshire |
Authorized Official Name and Position | Dawn Reed (EXECUTIVE ASSISTANT) |
Authorized Official Contact | 6033552244 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Maps Counseling Services, Inc. 23 Central Sq # 300 Keene NH 03431-3707 Ph: (603) 355-2244 | Maps Counseling Services, Inc. 23 Central Sq # 300 Keene NH 03431-3707 Ph: (603) 355-2244 |
NPI Number | 1255516449 |
---|---|
Provider Enumeration Date | 01/07/2008 |
Last Update Date | 10/13/2020 |
Certification Date | 10/13/2020 |
Medicare PECOS PAC ID | 8628061660 |
---|---|
Medicare Enrollment ID | O20051227000542 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1255516449 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TC0700X | Psychologist - Clinical | 554 (New Hampshire) | Primary |
Provider Name | John Richards |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1972557353 PECOS PAC ID: 3678543899 Enrollment ID: I20040727000609 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Julie A Higgins |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1225097561 PECOS PAC ID: 5890745962 Enrollment ID: I20050126000678 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Romulo Valdez |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1063618478 PECOS PAC ID: 6709897564 Enrollment ID: I20060509000323 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Gina M Pasquale |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1063554087 PECOS PAC ID: 7113066523 Enrollment ID: I20091124000533 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Susanne R Riemer |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1033408091 PECOS PAC ID: 2860666088 Enrollment ID: I20111123000627 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Vincent Mario Pignatiello |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1043695307 PECOS PAC ID: 9830409531 Enrollment ID: I20151110000028 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Deborah Christine Cheshire |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1518110436 PECOS PAC ID: 7618034745 Enrollment ID: I20180905003071 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Angele H Romano |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1407273238 PECOS PAC ID: 6507270295 Enrollment ID: I20210120001232 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Megan Smith |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1548453004 PECOS PAC ID: 7214341452 Enrollment ID: I20210128002068 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Meaghan E Pilling |
---|---|
Provider Type | Practitioner - Clinical Psychologist |
Provider Identifiers | NPI Number: 1013316439 PECOS PAC ID: 3173974367 Enrollment ID: I20240112000348 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | John L Sannicandro |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1497814453 PECOS PAC ID: 4587016258 Enrollment ID: I20240118000616 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Louise Howlett |
---|---|
Provider Type | Practitioner - Marriage And Family Therapist |
Provider Identifiers | NPI Number: 1053710541 PECOS PAC ID: 5799137154 Enrollment ID: I20240122001911 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Provider Name | Lucinda Nightingale |
---|---|
Provider Type | Practitioner - Marriage And Family Therapist |
Provider Identifiers | NPI Number: 1679699409 PECOS PAC ID: 6305298639 Enrollment ID: I20240123000068 |
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
News Archive
Researchers have found they can potentially target chemotherapy for breast cancer to only those women most likely to benefit, sparing the majority of patients from unnecessary side effects.
Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).
RaySearch Laboratories: JANUARY 1 - JUNE 30, 2011. Net sales for the period totaled SEK 47.6 M.
Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.
New research from Lloydspharmacy reveals that whilst an overwhelming number of women suffer from menstrual cramps, male partners' sympathy levels at that time of the month appear to be lacking. Although 87% of men claim to be very or fairly compassionate, a quarter of women (25%) who have suffered discomfort with 'Mother Nature's gift' say their partners are unsympathetic.
› Verified 2 days ago
Anew Behavioral Health Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 372 West St Ste 102, Keene, NH 03431 Phone: 603-338-0033 Fax: 800-480-7578 | |
Autumn Recovery Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 73 Court St Apt A, Keene, NH 03431 Phone: 603-363-4383 | |
Janet Robertson Lmft Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 163 Washington St, Keene, NH 03431 Phone: 802-368-1017 | |
Judyth A. Leavitt Psychotherapist P.l.l.c. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 100 Emerald St, Ste C, Keene, NH 03431 Phone: 603-903-2122 | |
Mindful Balance Therapy Center P.l.l.c Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 63 Emerald St # 102, Keene, NH 03431 Phone: 603-903-1414 Fax: 833-693-0222 | |
Aligned Associates Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 267 Court St, Keene, NH 03431 Phone: 603-209-3838 | |
Psychiatric Unit Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 580 Court St, Keene, NH 03431 Phone: 603-354-5454 |